Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00044694 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 156
- Enrollment target
NCT00044694 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 156 participants.
The verdict
NCT00044694, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 156 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, blinded, placebo-controlled, short-term, dose-response study to examine the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes. Patients will be individuals with type 2 diabetes treated with metformin for at least 3 months prior to screening. Patients whose diabetes management consists of diet and exercise will also be eligible for this study.
Interventions
- DRUG Placebo 0.01 mL
- DRUG Placebo 0.02 mL
- DRUG Placebo 0.03 mL
- DRUG Placebo 0.04 mL
- DRUG AC2993 2.5 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2002-08 |
| Est. Completion | 2003-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00044694
The ClinicalTrials.gov registry entry for NCT00044694 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo 0.01 mL is the first listed.
NCT00044694 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00044694 about?
NCT00044694 is a clinical study titled "Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus". This is a multicenter, randomized, blinded, placebo-controlled, short-term, dose-response study to examine the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes. Patients will be individuals with type 2 diabetes treated with metformin for at least 3 months ...
What is the current status of trial NCT00044694?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 156 participants. The study started on 2002-08. Estimated completion is 2003-05.
What interventions are being tested in trial NCT00044694?
The interventions under investigation include: Placebo 0.01 mL (DRUG), Placebo 0.02 mL (DRUG), Placebo 0.03 mL (DRUG), Placebo 0.04 mL (DRUG), AC2993 2.5 mcg (DRUG).
Who is sponsoring clinical trial NCT00044694?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.